Metformin versus SGLT-2 inhibitors: how low can we go?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35461613.
- Also identified by DOI 10.1016/j.kint.2022.02.012.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The progression of chronic kidney disease is difficult to stop once established. Metformin and sodium-glucose cotransporter 2 inhibitors show promise, but clinical trials with a head-to-head comparison in patients with more advanced (stage 3b-4) chronic kidney disease are largely lacking, partly for safety reasons. In this issue, Corremans et al. compare the effects of metformin and canagliflozin in rats with adenine-induced moderate (stage 2-4) chronic kidney disease. Metformin halted progression, whereas canagliflozin did not. This commentary puts the results in a wider clinical context.
Medical subject headings
- Metformin
- Renal Insufficiency, Chronic
- Sodium-Glucose Transporter 2 Inhibitors